Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares of Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Viridian Therapeutics Price Performance

NASDAQ:VRDN traded down $0.30 on Thursday, reaching $24.50. 1,076,002 shares of the company’s stock traded hands, compared to its average volume of 1,882,471. The stock has a 50-day simple moving average of $19.66 and a 200-day simple moving average of $20.97. Viridian Therapeutics, Inc. has a 12 month low of $13.18 and a 12 month high of $34.29. The firm has a market cap of $2.78 billion, a PE ratio of -7.27 and a beta of 0.91. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%.The business had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.07 earnings per share for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds have recently bought and sold shares of VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Viridian Therapeutics by 1.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after purchasing an additional 876 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Viridian Therapeutics by 33.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after purchasing an additional 310,998 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Viridian Therapeutics by 12.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after buying an additional 14,788 shares during the period. Envestnet Asset Management Inc. purchased a new position in Viridian Therapeutics in the 2nd quarter worth about $187,000. Finally, Creative Planning bought a new stake in Viridian Therapeutics during the 2nd quarter valued at about $179,000.

Analyst Upgrades and Downgrades

VRDN has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Wedbush boosted their target price on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the stock an “outperform” rating in a report on Tuesday, June 30th. The Goldman Sachs Group restated a “buy” rating and set a $39.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Weiss Ratings downgraded shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Finally, Truist Financial boosted their price target on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.93.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.